

November 14, 2014

OTC Markets Group, Inc.
304 Hudson Street, 3rd Floor
New York, NY 10013

Re: ValueRich, Inc. – “VRCH”

I have been engaged by ValueRich, Inc. (the “Company”) to prepare this legal opinion letter (the “Opinion Letter”) regarding the Company’s Quarterly report for the Quarter ended September 30, 2014 and submitted to OTC Markets on November 14, 2014, as required for posting on the OTC Markets filings page and the OTC Disclosure and News Service. OTC Markets Group is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

I am a citizen and resident of the United States of America, a member of the board of directors of Company, and an attorney duly licensed to practice law in the jurisdictions of Massachusetts, Rhode Island and Florida, including the District Courts of the United States in those jurisdictions. I am presently permitted to practice, and have never been prohibited from practice, before the United States Securities and Exchange Commission (the “SEC”).

I have examined certain corporate records and other documents of the Company and have considered certain issues of law as necessary and appropriate for purposes of rendering this Opinion Letter. All sources upon which I relied in forming this Opinion Letter are believed by me to be reliable. In connection with the preparation of this Opinion Letter, I have reviewed the following documents containing information concerning the Company and the securities of the Company (the “Securities”) that are publicly available through the OTC Markets (the “Information”):

- Initial Disclosure Document filed with the OTC Disclosure and News Service on August 26, 2011.
- Quarterly Report for the quarter ended June 30, 2011 filed with the OTC Disclosure and News Service on August 26, 2011.
- Quarterly Report for the quarter ended September 30, 2011 filed with the OTC Disclosure and News Service on November 16, 2011.
- Annual Report for the year ended December 31, 2011 filed with the OTC Disclosure and News Service on March 29, 2012.
- Quarterly Report for the quarter ended March 31, 2012 filed with the OTC Disclosure and News Service on May 14, 2012.
- Sales Contract, Ginn-LA Wilderness – filed with the SEC on January 22, 2010 as an exhibit to Form 8-K.
- Assignment of Contract – filed with the SEC on January 22, 2010 as an exhibit to Form 8-K.
- Development Work Agreement – filed with the SEC on January 22, 2010 as an exhibit to Form 8-K.
- Joint Venture Agreement - filed with the SEC on January 22, 2010 as an exhibit to Form 8-K.
- February 2010 Promissory Note filed with the OTC Disclosure and News Service on August 31, 2011.
- April 2011 Promissory Note filed with the OTC Disclosure and News Service on August 31, 2011.
- May 2011 Promissory Note filed with the OTC Disclosure and News Service on August 31, 2011.
- Articles of Incorporation filed with the OTC Disclosure and News Service on August 31, 2011.
- By-Laws filed with the OTC Disclosure and News Service on August 31, 2011.

- Annual Report for the year ended December 31, 2011 filed with the OTC Disclosure and News Service on March 24, 2012.
- Annual Report for the year ended December 31, 2012 filed with the OTC Disclosure and News Service on January 15, 2014.
- Interim financial Report for the quarter ending September 31, 2013 filed with the OTC Disclosure and News Service on January 15, 2014.
- Annual Report for the year ended December 31, 2013 filed with the OTC Disclosure and News Service on March 31, 2014.
- Quarterly Report for the quarter ended March 31, 2014 filed with the OTC Disclosure and News Service on May 15, 2014.
- Quarterly Report for the quarter ended June 30, 2014 filed with the OTC Disclosure and News Service on August 14, 2014.
- Quarterly Report for the quarter ended September 30, 2014 filed with the OTC Disclosure and News Service on November 14, 2014.

The Information (i) constitutes “adequate current public information” concerning the Securities and the Company and “is available” within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”), (iii) complies as to form with the OTC Market’s Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com, and (iv) has been posted through the OTC Disclosure and News Service. The financial statements are unaudited. The person responsible for the preparation of the Company’s financial statements contained in the Information is David D. Brooks, CPA, managing shareholder of D. Brooks and Associates CPA’s P.A. (“D. Brooks and Associates”), who issued a compilation report on such financial statements. D. Brooks and Associates is registered with the Public Company Accounting Oversight Board and regularly provides these services to SEC registrants. More information regarding D. Brooks and Associates can be found at their website at www.dbrookscpa.com. The Company’s transfer agent is Interwest Transfer Company, Inc., and is duly registered with the SEC. I reviewed a statement provided by the transfer agent to confirm the number of outstanding shares set forth in the Information. I have personally met with management and a majority of the directors of the Company, (ii) reviewed the Information published by the Company through the OTC Disclosure and News Service and (iii) discussed the Information with management and a majority of the directors of the Company. I am not currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws, and to the best of my knowledge after inquiry of management and the directors of the Company, neither of the Company, nor any 5% equity holder of the Company is under such investigation. No person other than OTC Markets is entitled to rely on this letter. I grant OTC Markets full and complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

Very truly yours,



DAVID P. LEMOIE, ESQ.